Astellas Pharma Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALPMY Over the counter 2830 www.astellas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Astellas Pharma Inc.

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices - May 12th, 2025 8:28 am
Notice of Nominees for Directors - May 7th, 2025 10:00 am
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses - May 1st, 2025 1:00 pm
Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock? - Apr 29th, 2025 4:00 pm
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year? - Apr 28th, 2025 1:40 pm
Astellas Pharma and JFCR partner for oncology research - Apr 3rd, 2025 9:12 am
Astellas and Yaskawa form JV for cell therapy product manufacture - Mar 7th, 2025 10:34 am
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing - Mar 6th, 2025 4:02 am
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize - Feb 27th, 2025 3:00 pm
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - Feb 12th, 2025 11:32 pm
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo - Feb 11th, 2025 7:13 pm
Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer - Feb 10th, 2025 10:53 pm
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) - Feb 10th, 2025 10:00 pm
Astellas seeks conditional approval for GA treatment in Japan - Feb 5th, 2025 4:03 pm
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan - Feb 5th, 2025 8:59 am
Astellas Makes Announcement about Management Structure - Feb 4th, 2025 6:30 am
U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - Jan 8th, 2025 11:30 pm
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer - Jan 8th, 2025 9:55 am
Astellas and Sangamo sign capsid deal for neurological diseases - Dec 20th, 2024 9:37 am
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - Dec 19th, 2024 7:30 am